Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach

Journal of Medicinal Chemistry

Volumn 53, Issue 18, 2010, Pages 6618-6628

  Oyarzabal, Julen ^a   Zarich, Natasha ^a   Albarran, María Isabel ^a   Palacios, Irene ^a   Urbano Cuadrado, Manuel ^a   Mateos, Genoveva ^a   Reymundo, Isabel ^a   Rabal, Obdulia ^a   Salgado, Antonio ^a   Corrionero, Ana ^a   Fominaya, Jesús ^a   Pastor, Joaquin ^a   Bischoff, James R ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CGP 57380; INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE INTERACTING KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INTERACTING KINASE 2; MOLECULAR SCAFFOLD; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MKNK1 PROTEIN, HUMAN; MKNK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COMPUTER SIMULATION; DRUG SCREENING; ENZYME INHIBITOR INTERACTION; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; FACTUAL DATABASE; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77956741769     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1005513     Document Type: Article

References (50)

1. De Benedetti, A.; Graff, J. R. eIF-4E expression and its role in malignancies and metastases Oncogene 2004, 23, 3189-3199
2. Gingras, A. C.; Raught, B.; Sonenberg, N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation Annu. Rev. Biochem. 1999, 68, 913-963
3. Polunovsky, V. A.; Rosenwald, I. B.; Tan, A. T.; White, J.; Chiang, L.; Sonenberg, N.; Bitterman, P. B. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc Mol. Cell. Biol. 1996, 16, 6573-6581
4. Wendel, H.-G.; Silva, R. L. A.; Malina, A.; Mills, J. R.; Zhu, H.; Ueda, T.; Watanabe-Fukunaga, R.; Fukunaga, R.; Teruya-Feldstein, J.; Pelletier, J.; Lowe, S. W. Dissecting eIF4E action in tumorigenesis Genes Dev. 2007, 21, 3232-3237
5. Waskiewicz, A. J.; Flynn, A.; Proud, C. G.; Cooper, J. A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2 EMBO J. 1997, 16, 1909-1920
6. Fukunaga, R.; Hunter, T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates EMBO J. 1997, 16, 1921-1933
7. Waskiewicz, A. J.; Johnson, J. C.; Penn, B.; Mahalingam, M.; Kimball, S. R.; Cooper, J. A. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in-vivo Mol. Cell. Biol. 1999, 19, 1871-1880
8. Ueda, T.; Watanabe-Fukunaga, R.; Fukuyama, H.; Nagata, S.; Fukunaga, R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development Mol. Cell. Biol. 2004, 24, 6539-6549
9. Makara, G. M. On sampling of fragment space J. Med. Chem. 2007, 50, 3214-3221
10. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
11. Abad-Zapatero, C.; Metz, J. T. Ligand efficiency indices as guideposts for drug discovery Drug Discovery Today 2005, 10, 464-469
12. Oyarzabal, J; Howe, T.; Alcazar, J.; Andres, J. I.; Alvarez, R. M.; Dautzenberg, F.; Iturrino, L.; Martinez, S.; Van der Linden, I. Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concentrating hormone antagonists J. Med. Chem. 2009, 52, 2076-2089
13. Alex, A. A.; Flocco, M. M. Fragment-based drug discovery: What has it achieved so far? Curr. Top. Med. Chem. 2007, 7, 1544-1567
14. Albert, J. S.; Blomberg, N.; Breeze, A. L.; Brown, A. J. H.; Burrows, J. N.; Edwards, P. D.; Folmer, R. H. A.; Geschwindner, S.; Griffen, E. J.; Kenny, P. W.; Nowak, T.; Olson, L.-L.; Sanganee, H.; Shapiro, A. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZenecas drug discovery programmes Curr. Top. Med. Chem. 2007, 7, 1600-1629
15. Ji, H.; Stanton, B. Z.; Igarashi, J.; Li, H.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors J. Am. Chem. Soc. 2008, 130, 3900-3914
16. ACD/Solubility DB, version 12.0; Advanced Chemistry Development, Inc.: Toronto, Canada, 2008; http://www.acdlabs.com.
17. Oyarzabal, J; Pastor, J.; Howe, T. Optimizing the performance of in silico ADMET general models according to local requirements: MARS approach. Solubility estimations as case study J. Chem. Inf. Model. 2009, 49, 2837-2850
18. Jauch, R.; Cho, M. K.; Jäkel, S.; Netter, C.; Schreiter, K.; Aicher, B.; Zweckstetter, M.; Jäckle, H.; Wahl, M. C. Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment EMBO J. 2006, 25, 4020-4032
19. Jauch, R.; Wahl, M. C.; Netter, C.; Jäkel, S.; Schreiter, K.; Aicher, B.; Jäckle, H. Structures of MNK2 Kinase Domain and MNK2 (D228G) Kinase Domain. Unpublished data deposited in the Protein Data Bank (PDB).
20. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748
21. Kinase Knowledgebase (KKB) is available from Eidogen-Sertanty, Inc. at http://www.eidogen-sertanty.com (accessed May 2009).
22. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132
23. Knauf, U.; Tschopp, C.; Gram, H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2 Mol. Cell. Biol. 2001, 21, 5500-5511
24. Anderson, D. R.; Meyers, M. J.; Vernier, W. F.; Mahoney, M. W.; Kurumbail, R. G.; Caspers, N.; Poda, G. I.; Schindler, J. F.; Reitz, D. B.; Mourey, R. J. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2) J. Med. Chem. 2007, 50, 2647-2654
25. Wang, S.; Wood, G.; Duncan, K.; Meades, C.; Gibson, D.; Mclachlan, J.; Fischer, P. Preparation of 2-Substituted 4-Thiazolylpyrimidines as Protein Kinase Inhibitors with Improved Solubility Properties. Patent WO05116025 A2, 2005; 216 pp.
26. Jaekel, S.; Reuter, T.; Murfin, S.; Coulter, T. S.; Taylor, S. Pyrrolopyrimidines for Pharmaceutical Compositions. Patent WO08006547 A2, 2008; 60 pp.
27. Aicher, B.; Coulter, T. S.; Jaekel, S.; Kelter, A.-R.; Murfin, S.; Reuter, T.; Taylor, S. Thienopyrimidines Having MNK1/MNK2 Inhibiting Activity for Pharmaceutical Compositions. Patent WO07115822 A1, 2007; 95 pp.
28. Coulter, T. S.; Taylor, S.; Murfin, S.; Thammalaksa, V.; Aicher, B.; Jaekel, S.; Reuter, T. Preparation of Pyrazolopyrimidines as Inhibitors of Kinase Activity. Patent WO06066937 A2, 2006; 122 pp.
29. Bender, A.; Glen, R. C. A discussion of measures of enrichment in virtual screening: comparing the information content of descriptors with increasing levels of sophistication J. Chem. Inf. Model. 2005, 45, 1369-1375
30. Bender, A.; Mussa, H. Y.; Reiling, S.; Glen, R. C. Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): evaluation of performance J. Chem. Inf. Model. 2004, 44, 1708-1718
31. Glen, R. C.; Bender, A.; Arnby, C. H.; Carlsson, L.; Boyer, S.; Smith, J. Circular fingerprints: flexible molecular descriptors with applications from physical chemistry to ADME IDrugs 2006, 49, 199-204
32. Pipeline Pilot, version 7.5; Accelrys, Inc. (10188 Telesis Court, Suite 100, San Diego, CA 92121); http://accelrys.com/.
33. FTrees, version 2.0. BioSolveIT GmbH (An der Ziegelei 79, 53757 Sankt Augustin, Germany); http://www.biosolveit.de.
34. Grant, J. A.; Gallardo, M. A.; Pickup, B. T. A fast method of molecular shape comparison. A simple application of Gaussian description of molecular shape J. Comput. Chem. 1996, 17, 1653-1666
35. Nicholls, A.; MacCuish, N. E.; MacCuish, J. D. Variable selection and model validation of 2-D and 3-D molecular descriptors J. Comput.-Aided Mol. Des. 2004, 18, 451-474
36. Nicholls, A.; Grant, A. J. Molecular shape and electrostatics in the encoding of relevant chemical information J. Comput.-Aided Mol. Des. 2005, 19 (9-10) 661-686
37. Mitchell, T. J. An algorithm for the construction of "D- optimal" experimental designs Technometrics 1974, 16, 203-210
38. St. John, R. C.; Draper, N. R. D-Optimality for regression designs: a review Technometrics 1975, 17, 15-23
39. Dumouchel, W.; Jones, B. A simple bayesian modification of D-optimal designs to reduce dependence on an assumed model Technometrics 1994, 36, 37-47
40. Myers, R. H. Response Surface Methodology; Allyn and Bacon Inc.: Boston, MA, 1971.
41. Giraud, E.; Luttmann, C.; Lavelle, F.; Riou, J.-L.; Mailliet, P.; Laoui, A. Multivariate data analysis using D-optimal designs, partial least squares, and response surface modeling: a directional approach for the analysis of farnesyltransferase inhibitors J. Med. Chem. 2000, 43, 1807-1816
42. SIMCA-P+, version 11.0; Umetrics AB (Box 7960, SE-907 19 Umea, Sweden); www.umetrics.com.
43. MODDE, version 8.0; Umetrics AB (Box 7960, SE-907 19 Umea, Sweden); www.umetrics.com.
44. Urbano-Cuadrado, M.; Rabal, O.; Oyarzabal, J. Centralizing discovery information: from logistics to knowledge at a public organisation. Comb. Chem. High Throughput Screening, in press.
45. Hajduk, P.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 2005, 48, 2518-2525
46. Katritch, V.; Jaakola, V. P.; Lane, J. R.; Lin, J.; Ijzerman, A. P.; Yeager, M.; Kufareva, I.; Stevens, R. C.; Abagyan, R. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists J. Med. Chem. 2010, 53, 1799-1809
47. Molecular Operating Environment (MOE); Chemical Computing Group Inc. (1010 Sherbrooke St. W, Suite 910, Montreal, Quebec, Canada); http://www.chemcomp.com.
48. OpenEye Scientific Software Inc. (9 Bisbee Court, Suite D, Santa Fe, NM 87508); http://www.eyesopen.com.
49. Boström, J. Reproducing the conformations of protein-bound ligands: a critical evaluation of several popular conformational searching tools J. Comput.-Aided. Mol. Des. 2001, 15, 1137-1152
50. Jennings, A.; Tennant, M. Selection of molecules based on shape and electrostatic similarity: proof of concept of "electroforms" J. Chem. Inf. Model. 2007, 47, 1829-1838